COMPARATIVE STUDY BETWEEN BOTULINUM TOXIN A AND PLATELET RICH PLASMA IN THE TREATMENT OF MYOFASCIAL PAIN WITHIN MASSETER MUSCLE (A RANDOMIZED CLINICAL TRIAL) | ||
| Alexandria Dental Journal | ||
| Article 12, Volume 49, Issue 2, August 2024, Pages 91-99 PDF (366.87 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/adjalexu.2023.197369.1356 | ||
| Authors | ||
| Amira Mohamed Aglan* 1; moustafa mohamed eldibany2; Marwa Noureldin3; Hoda Mohamed Abdel-Naby4 | ||
| 1Oral and Maxillofacial surgery, faculty of dentistry, Alexandria university, Alexandria, Egypt | ||
| 2Professor of Oral and Maxillofacial Surgery, Conservative Dentistry, Faculty of Dentistry, Alexandria University, Alexandria, Egypt. | ||
| 3oral and maxillofacial surgery, Faculty of Dentistry, Alexanria university, Alexandria, Egypt | ||
| 4Physical Medicine, Rheumatology and Rehabilitation department. Faculty of Medicine Alexandria University | ||
| Abstract | ||
| Introduction: Masticatory myofascial trigger points (TrPs) are considered from the main sources of pain of non-dental origin in orofacial area. Botulinum toxin A (BTX-A) may relieve myofascial pain through inhibition of α-motor nerve endings. Platelet rich plasma (PRP) injection into the masseter muscle aids in the relief of pain owing to its analgesic and anti-inflammatory effect. Objective: To evaluate and compare the effectiveness of BTX-A and PRP injections on muscle activity, visual analogue scale (VAS) for pain, pressure pain intensity (PPI) and jaw functional limitation scale (JFLS) in patients having myofascial TrPs within the masseter muscle. Materials and Methods: Twenty six patients suffering from myofascial TrPs within the masseter muscle were randomized into two groups: Group 1 (n=13) received BTX-A injection and group 2 (n=13) received PRP injection. Muscle activity during rest and during function were determined after 6 months, VAS for pain, PPI and JFLS scores were determined at the 1, 3 and 6-months follow-up visits. Results: There was significant improvement seen in both groups at the 1-month follow-up. BTX group exhibited significant changes regarding VAS, PPI and JFLS scores at the 3-months follow-up, while PRP group showed significant changes regarding VAS and JFLS only. At the 6-months follow-up, both groups’ patients relapsed to initial records. Conclusion: This study showed that BTX has superior results when compared to PRP in alleviation of myofascial pain. | ||
| Keywords | ||
| Myofascial pain; trigger points; botulinum toxin type A; platelet rich plasma | ||
|
Statistics Article View: 200 PDF Download: 307 |
||
